Backgrounds: In addition to its curative use for early stage lung cancer, stereotactic ablative radiotherapy is also indicated for pulmonary metastatic disease. Aims of this study were to retrospectively analyze treatment outcomes and to find prognostic factors for survivals. Methods: Treatment outcomes and toxicities of 85 cases of SABR in 72 patients were retrospectively reviewed from September 2012 to April 2015. Prognostic factors were analyzed using Cox proportional hazards regression. Results: The local failure-free survival rate at 2 years was 98%. Of the case, 1-year and 2-year progression-free survival rates were 62% and 48%, and overall survival rates were 90% and 72%, respectively. Multivariate analyses demonstrated that controlled primary cancer (P = 0.01), absence of extra-pulmonary metastatic disease (P < 0.01) and disease-free interval longer than 1 year (P < 0.01) favorably affected progression-free survival. Furthermore, the absence of extra-pulmonary metastatic disease (P < 0.01) increased overall survival as well. Grade 1 or 2 radiation pneumonitis was found in 37 cases, and Grade 1 chest wall pain was found in 1 case. Conclusions: Stereotactic ablative radiotherapy demonstrated good local control with tolerable adverse effects for pulmonary metastasis. The presence or absence of extra-pulmonary metastasis was found to be prognostic factor of mortality after stereotactic ablative radiotherapy treatment.
Introduction
The pulmonary microenvironment consists of an extensive capillary system for all blood cells (1) , permitting easy dissemination for circulating tumor cells and making the lungs one of the most common metastatic sites of various solid tumors. An intermediate state of metastasis called 'oligometastasis', where the number and sites of metastatic lesions are limited and likely to be controlled with localized treatment, was first proposed in 1995 (2) . Clinical and laboratory data support this concept (3) . Pulmonary metastasectomy has been proposed as the standard treatment to treat lung metastasis because the long-term outcomes are favorable, with overall survival (OS) of 36% at 5 years, 26% at 10 years and 22% at 15 years (4) . Localized or ablative treatment seems to be appropriate because second-line chemotherapy has a limited effect on most tumors once metastasis has occurred (1) . However, a pulmonary metastasectomy is not often feasible due to its tumor burden. In such cases, stereotactic ablative radiotherapy (SABR) can be used as an alternative method of treatment. SABR is an external beam radiotherapy technique that spares normal organs with high conformity, allowing small tumors to be treated without major complications. The rationale for the use of SABR has been established for early stage non-small cell lung cancer. A systemic review reported that survival outcomes achieved by SABR for primary lung cancer are comparable to those of surgical outcomes (5), suggesting that SABR is an alternative for patients with multiple comorbidities unable to undergo surgical resection. These results thus suggest a role for SABR in pulmonary metastatic disease.
The primary endpoint of this study was to retrospectively analyze OS in patients with pulmonary metastasis treated with SABR. The secondary endpoints were clinical outcomes including local failure-free survival (LFFS), progression-free survival (PFS) and identifying factors predicting clinical outcomes after SABR treatment.
Materials and methods
About 72 patients with 85 pulmonary metastatic lesions treated at Seoul National University Hospital from September 2012 to April 2015 were reviewed. The patients were diagnosed based on computed tomography (CT) or [ 18 F]fluorodeoxyglucose positron emission (PET) scans using the following inclusion criteria: ≤5 pulmonary metastatic lesions with the longest diameter ≤5 cm; any previous therapeutic modality; all histological types of metastatic and primary lesions; and all performance status level excluding brain metastasis or leptomeningeal seeding. CT simulation was done using four-dimensional-CT scanning (Real-time Position Management™ System, Varian Medical Systems, Palo Alto, CA, and Brilliance CT big bore, Philips, Cleveland, OH, USA). After the gross tumor volume was outlined for each of the 10-phase CT images with a 2 mm slice thickness, the internal target volume (ITV) was defined on axial maximum intensity projection images. Thereafter, the clinical target volume was declared as the same volume as the ITV. The planning target volume (PTV) was defined isotropically from the ITV as 3-7 mm. Most patients were treated with 48-60 Gy in four fractions, except for two patients (one patient with 45 Gy in five fractions and the other with 50 Gy in five fractions). Volumetric arc therapy plans were generated with the Eclipse™ system (Varian Medical Systems). After kilovoltage cone-beam CT images were taken and matched with the original plan in each treatment session, treatment was delivered with a 6 MV flattening filter-free beam using two coplanar partial arcs from the Truebeam STx™ (Varian Medical Systems). The partial arc angles were determined considering the dose to the contralateral lung and the tumor location. All plans had the isocenter located in the PTV and optimized with the progressive resolution optimizer (PRO3 ver.10; Varian Medical Systems).
The dose constraints of organ at risks (OARs) were adapted from the National Comprehensive Cancer Network Clinical Practice Guideline in Oncology (NCCN Guidelines ® ; National Comprehensive Cancer Network, Fort Washington, PA) for Non-Small Cell Lung Cancer (https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf).
For example, when prescribed for four fractions of 48 Gy, maximum dose constraints for SABR for spinal cord, esophagus, bronchi and rib are 18 Gy, 27 Gy, 24 Gy and 30 Gy, respectively. Our institution mostly does not consider volumes of OARs due to their tiny volumes irradiated.
Survival was calculated from the first day of SABR. Patients were seen in clinic at least once during treatment. Follow-up was performed 6 weeks after treatment ended and thereafter every 3 months. Local failure was defined as a recurrence in the PTV. Any progression including distant metastasis or recurrence in the same lobe was defined as disease progression. PFS analyzed from the start of SABR until the date of disease progression or death from any cause. The disease-free interval was defined as the time interval from primary site treatment to appearance of metastasis in the lung. All recurrences were diagnosed based on PET-CT images or histological confirmation.
Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.0. Survival functions for LFFS, PFS and OS were estimated with the Kaplan-Meier method and compared by log-rank test. Cox proportional hazards regression analysis was used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs) of clinical factors for each PFS and OS. Univariate Cox regression analysis was used first to determine clinical factors affecting outcomes. All factors with a P value of <0.1 were considered to be candidates for the backward stepwise Cox regression model for variable selection with entry cutoff level of 0.1 and stay cutoff 0.05. With selected variables, a multivariable Cox proportional hazards regression model was generated for each PFS and OS.
All statistical calculations were performed with Stata 10 (StataCorp, College Station, TX, USA) and R version 3.1.0 (http://www. r-project.org/) with 'rms' library of version 4.4-0.
Results
The median follow-up duration was 15.2 months (range, 0.2-30.7 months), and 14 patients died during observation. The patient characteristics are summarized in Table 1 .
The patient cohort consisted of 45 (62.5%) men and 27 (37.5%) women with median age of 65 years (range, 19-90 years). All patients, except one, had favorable performance status, equal or less than Eastern Cooperative Oncology Group (ECOG) 2. Median tumor diameter was 1.2 cm (range, 0.5-4.2 cm) as measured on CTbased images. We did not routinely perform biopsies on metastatic lesions. The most common primary lesion per tumor was lung (n = 36, 42.3%), followed by colorectum (n = 15, 17.6%) and liver (n = 14, 16.5%). Other primary cancers included breast (n = 2), sarcoma (n = 4), head and neck (n = 3), neuroendocrine (n = 2), genitourinary (n = 2), malignant peripheral nerve sheath tumor (n = 2) and gynecological (n = 1). The majority of patients at consultation had one lung metastasis (n = 55, 76.4%), no extrapulmonary metastasis (n = 63, 87.5%), controlled primary lesions (n = 61, 84.7%) and disease interval >1 year (n = 29, 40.3%).
One in-field failure was detected at 11.6 months (Fig. 1a) ; therefore, the 2-year LFFS rate was 98%. The 1-and 2-year OS rates were 90% and 72%, respectively (Fig. 1b) . The 1-and 2-year PFS rates were 62% and 48%, respectively. Extra-pulmonary metastasis indicates ongoing disease progression, so we estimated survival in patients without extra-pulmonary metastasis (n = 9). As shown in Fig. 1c , no difference in survival rate was observed when patients with or without extra-pulmonary metastasis were included. Log-rank test (Table 2) revealed that the primary lesion, control of the primary lesion, extra-pulmonary metastasis and disease-free interval were associated with PFS rate and extra-pulmonary metastasis with OS rate, respectively. However, tumor diameter, tumor position, number of lung metastases and total radiation dose did not affect the PFS nor OS rates.
To evaluate risk factors of prognosis properly, we established Cox proportional hazard regression models both in univariate and multivariate fashion. Univariate Cox proportional hazard regression model for PFS revealed that pulmonary metastases from liver associated with increased risk of disease progression on compared with other primary sites. In addition, control of the primary lesion, extrapulmonary metastasis and disease-free interval were associated with disease progression as well. Stepwise variable selection with factors representing P value < 0.10 led to final Cox proportional hazard model. Final model reported that controlling the primary lesion (HR 0.32, 95% CI 0.13-0.77, P = 0.01) and disease-free interval >1 year (HR 0.31, 95% CI 0.15-0.64, P < 0.01) were associated with longer PFS rate. Extra-pulmonary metastasis (HR 5.72, 95% CI 2.00-16.37, P < 0.01) also demonstrated a greater risk of progression. However, no significant association was found between primary lesion and PFS in multivariate analysis (Table 3) .
For OS, the presence of extra-pulmonary metastasis and control of primary lesion were related to mortality in univariate Cox proportional hazard model. Final model reported that only extrapulmonary metastasis was significantly associated with higher risk of mortality (HR 9.44, 95% CI 2.99-29.7, P < 0.01)
A single case about complaint of chest wall pain was reported as a Grade 1 toxicity. The other cases were mostly radiation pneumonitis: 34 cases of Grade 1 and 3 cases of Grade 2. Of the 34 cases, 6 were symptomatic, but no one required mediation. No Grade 3 or higher toxicities were reported.
Discussion
Our findings demonstrated that SABR in patients with pulmonary metastasis resulted in good local control with tolerable side effects. The multivariate analysis revealed extra-pulmonary metastasis affected OS. It also showed that control of the primary lesion, disease-free interval and extra-pulmonary metastasis affected PFS. Based on these results, we could possibly recommend SABR to the patients with those factors such as control of primary lesion, longer disease-free interval and absence of extra-pulmonary metastasis. Previous studies of SABR or metastasectomy in patients with pulmonary metastasis are summarized in Table 4 . Several studies (6) (7) (8) (9) have shown that 1-year LFFS and OS rate are 79-91% and 71-84.1%, respectively, when pulmonary metastatic lesions are treated with SABR. We demonstrated comparable 1-year LFFS and OS rates in the present study. Although pulmonary metastasectomy is a preferred method to treat pulmonary metastatic disease, Widder et al. (10) compared pulmonary metastasectomy with SABR retrospectively and demonstrated that the 1-year OS rate was 98% for SABR and 87% for metastasectomy (log-rank test, P = 0.43). Twoyear local control was 94% for SABR and 90% for metastasectomy, indicating that the clinical outcomes of surgery were not superior to those of SABR.
Overall, our results appeared better for local control and OS rate than those of previous studies although direct comparison is not possible. Our tumor size was a median of 1.2 cm, which is rather smaller than that of other series. Moreover, 55 (76.4%) patients had a single metastasis in the lung and 63 (87.5%) had no extrapulmonary disease at the time of SABR consultation, so better local and OS rates would be expected. In addition, potential local failure may not have been observed in our study due to the short duration follow-up period.
Various prognostic factors have been reported in previous studies. Some series have pointed out that the disease-free interval is a prognostic factor for survival. Inoue et al. (11) found that a diseasefree interval <36 months is associated with poorer 3-and 5-year OS rates, compared with those of a longer disease-free interval. Takahashi et al. (12) reported that a disease-free interval <31.9 months is related to worse OS rate. Although the prognostic significance of the disease-free interval was unclear for OS in the present study, it remained a strong prognostic factor for disease progression. Tumor size and extra-thoracic disease were associated with OS in the univariate analysis (13) . However, significance was retained in the multivariate analysis only for extra-thoracic disease. We found that the presence of extra-pulmonary disease was strongly associated with poor OS. Though Ricardi et al. (14) reported that tumor volume was significantly associated with OS and PFS, another study reported-similar to ours-that the association with local control was unclear (15) . In a single-dose SABR, trends were observed between higher dose or smaller tumor volume and better local control, but no significant differences were found (7), which was similar to our results. One study demonstrated that pulmonary metastasis from colorectal cancer was significantly associated with a higher incidence of local failure (16) . In that study, 1-and 2-year local failure rates were 8.7% and 16.2%, respectively, with a median 22-month follow-up. However, we found that primary hepatic, instead of colorectal tumors, were associated with the lowest progression-free and OS rates in log-rank test. Another study showed that lesions from breast cancer are better controlled than those from hepatic or colorectal cancer (17) .
According to our results, the number of lung metastases was not associated with clinical outcomes, whereas substantial differences in clinical outcomes were detected between patients with extrapulmonary metastasis. Based on these results, the use of SABR should be extended to pulmonary oligometastases, particularly in patients with good prognosis.
There are several limitations in our study. Firstly, this was a retrospective study at a single institution, thus potential selection bias may have affected the results. Secondly, a longer follow-up duration is needed to consolidate our clinical outcomes. It should also be noticed that SABR was given to patients with unfavorable prognosis. Nevertheless, our clinical outcomes were relatively good, particularly for PFS.
Conclusion
In conclusion, our results demonstrate that SABR resulted in favorable local control rates with minimal side effects for treating patients with pulmonary metastasis. We also identified prognostic factors of PFS and OS rates. Control of primary lesion, disease-free interval and the presence of extra-pulmonary metastasis were important for PFS. For OS, the presence of extra-pulmonary metastasis was found to be a strong prognostic factors. Abbreviations: LFFS, local failure-free survival; NR, not reported; SNUH, Seoul National University Hospital.
